The development of a canine single-chain phage antibody library to isolate recombinant antibodies for use in

Małgorzata Lisowska1, Erin G Worrall2, Filip Zavadil-Kokas3

  • 1International Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland.

Cell Reports Methods
|March 25, 2025
PubMed

Insights

Researchers developed a novel method to clone canine antibody genes, creating a versatile platform for discovering new medicines for both canine and human diseases.

Area of Science:

  • Immunology and Biotechnology
  • Canine and Comparative Medicine

Background:

  • Developing immunotolerant monoclonal antibodies is crucial for advancing veterinary and human medicine.
  • Canine models offer unique insights into human disease pathogenesis and treatment.

Purpose of the Study:

  • To establish a robust methodology for cloning and archiving the canine variable domain antibody repertoire.
  • To create a synthetic antibody platform for developing novel therapeutics and preclinical models.

Main Methods:

  • Utilized 5'RACE PCR to clone naive, somatically mutated variable domain repertoire from canine B cell mRNA.
  • Developed degenerate primers for cloning variable domain genes into archival plasmid libraries.
  • Constructed a single-chain variable fragment (scFv) M13 phage library through combinatorial ligation.
  • Employed next-generation sequencing (long-read and short-read) for library annotation, including CDR diversity and immunoglobulin gene subfamily distribution.

Main Results:

  • Successfully cloned and archived a diverse canine antibody variable domain repertoire.
  • Annotated library features, revealing CDR diversity and IGHV/IGKV/IGLV subfamily distribution.
  • Generated a synthetic immunoglobulin G targeting the canine immune checkpoint receptor PD-1.

Conclusions:

  • The developed synthetic platform enables perpetual cloning and annotation of antibody variable domain genes.
  • This platform facilitates the development of improved preclinical models for complex human diseases.
  • The methodology accelerates the discovery of novel canine and human therapeutics.